Detailed product reference
Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.
Product overview
Dupixent is an IL-4-receptor-alpha antibody with Japanese 200/300 mg syringe and pen presentations.
Read source section ↗Mechanism of action
Blocks IL-4/IL-13 signaling involved in type-2 inflammation; it is not an acute asthma reliever.
Read source section ↗Japanese indications & eligibility
Uses vary by formulation and include selected dermatitis, urticaria, asthma and additional 300 mg indications.
Read source section ↗Administration & dose differences
Some adult regimens load 600 mg then 300 mg every two weeks; pediatric and other indication schedules differ.
Read source section ↗Adverse effects & key risks
Watch injection reactions, ocular inflammation, hypersensitivity and eosinophilic conditions.
Read source section ↗Contraindications & special populations
Ingredient hypersensitivity is contraindicated; assess helminth infection, vaccination and other treatment changes.
Read source section ↗Drug interactions
Review live vaccines and clinician-supervised steroid/combination therapy changes.
Read source section ↗Assessment & monitoring
Follow disease control, ocular symptoms and injection technique; verify handling and disposal training.
Read source section ↗Storage & handling
Refrigerate at 2–8°C; once removed, keep boxed ≤25°C and use within 14 days. Do not freeze, shake or heat.
Read source section ↗Sources & verification
Product checked ·
- PMDA electronic package insert ↗www.pmda.go.jp
Primary source for mechanism, indications, doses and risks; revision: 2026-03.
- Manufacturer information ↗pro.campus.sanofi
Official product or related information; professional portals may require identity confirmation.
- Wikipedia: ingredient background ↗en.wikipedia.org
Background reference; Japanese approvals and administration are governed by PMDA sources.
